Alliance Pharma (APH)

Sector:

Pharma and Biotech

Index:

FTSE AIM 50

39.70p
   
  • Change Today:
      0.20p
  • 52 Week High: 71.80
  • 52 Week Low: 34.50
  • Currency: UK Pounds
  • Shares Issued: 540.40m
  • Volume: 866,514
  • Market Cap: £214.54m
  • RiskGrade: 119

Alliance Pharma overseas transformation continues

By Iain Gilbert

Date: Wednesday 19 Sep 2018

LONDON (ShareCast) - (Sharecast News) - As Alliance Pharma's overseas transformation continued throughout the first half of its trading year, the AIM-listed group managed to record some growth in both revenues and profits.
Revenues grew 10% year-on-year to £54.5m, leading to a 12% increase in gross profits to £32.4m and a 1% improvement in EBITDA to £13.8m. However, reported basic earnings per share tumbled 35% to to 1.85p.

Free cash flow contracted 9% to £10.1m and net debt grew 19% during the half to £86.3m.

Alliance said its acquisition of Nizoral, announced in June 2018, significantly enhanced its presence in the Asia Pacific region, providing both increased scale and the opportunity to further develop its business across China, Japan and Thailand.

Also during the period, the group established a new US affiliate office to manage the sales of Vamousse head lice treatment in its largest market and the Medicines & Healthcare Products Regulatory Agency approved Alliance's UK marketing authorisation application for Xonvea, its prescription product for the treatment of nausea and vomiting in pregnancy.

Chairman David Cook said: "The first half of 2018 has seen continued transformation of the Alliance business, with the creation of an Alliance office in the US, the acquisition of Nizoral bringing increased scale and opportunities for us in the Asia Pacific region and the recent UK approval of Xonvea, offering additional opportunities for growth in the medium term."

As of 0925 BST, Alliance shares had dipped 2.64% to 88.60p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Alliance Pharma Market Data

Currency UK Pounds
Share Price 39.70p
Change Today 0.20p
% Change 0.51 %
52 Week High 71.80
52 Week Low 34.50
Volume 866,514
Shares Issued 540.40m
Market Cap £214.54m
RiskGrade 119

Alliance Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
78.84% above the market average78.84% above the market average78.84% above the market average78.84% above the market average78.84% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Price Trend
67.54% below the market average67.54% below the market average67.54% below the market average67.54% below the market average67.54% below the market average
5.26% below the sector average5.26% below the sector average5.26% below the sector average5.26% below the sector average5.26% below the sector average
Income
10.21% below the market average10.21% below the market average10.21% below the market average10.21% below the market average10.21% below the market average
14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average
Growth
89.09% below the market average89.09% below the market average89.09% below the market average89.09% below the market average89.09% below the market average
89.19% below the sector average89.19% below the sector average89.19% below the sector average89.19% below the sector average89.19% below the sector average

What The Brokers Say

Strong Buy 4
Buy 0
Neutral 3
Sell 0
Strong Sell 0
Total 7
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Alliance Pharma Dividends

  Latest Previous
  Final Interim
Ex-Div 22-Jun-23 22-Dec-22
Paid 18-Jul-23 19-Jan-23
Amount 1.18p 0.59p

Trades for 28-Mar-2024

Time Volume / Share Price
16:35 66,726 @ 39.70p
16:35 196 @ 39.70p
16:35 738 @ 39.70p
16:35 62 @ 39.70p
16:35 661 @ 39.70p

Alliance Pharma Key Personnel

CEO Peter Butterfield
CFO Andrew Franklin
Chair Camillo Pane

Top of Page